RT Journal Article
T1 Persistence profile to nucleos(t)ide analogue treatment for patients with chronic hepatitis B
A1 Borrego Izquierdo, Yolanda
A1 Gomez Fernandez, Encarnacion
A1 Monje Agudo, Patricia
A1 Jimenez Galan, Rocio
A1 Almeida-Gonzalez, Carmen V.
A1 Ferrit Martin, Monica
A1 Morillo Verdugo, Ramon
K1 Hepatitis B
K1 Persistence
K1 Treatment
K1 Nucleoside analogues
K1 Nucleotide analogues
K1 Phamaceutical care
K1 Long-term persistence
K1 Medication compliance
K1 Adherence
K1 Protease
K1 Outcomes
K1 Therapy
AB Background There are currently five approved nucleos(t)ide analogues (NUCs) for the management of chronic hepatitis B (CHB): lamivudine, adefovir dipivoxil, telbivudine, entecavir, and tenofovir disoproxil fumarate.Objective To determine the persistence rates among patients receiving NUCs for CHB at weeks 48, 96 and 144, compare them in these periods, and analyse the evolution of treatment persistence.Methods We conducted a retrospective study that included patients with CHB who initiated antiviral therapy and were attended to by the pharmaceutical care office between January 2002 and December 2011. Patients included in a clinical trial or patients who did not collect their medication personally were excluded. There were two different analyses: a comparative analysis of the persistence rates in three periods (weeks 1-48, weeks 48-96, and weeks 96-144); and a Kaplan-Meier analysis to evaluate the evolution of persistence.Results A total of 102 patients were included. Persistence rates were different in the three periods. They decreased during the course of the different periods, and the decline was more rapid between the first and second period. There were statistically significant differences in the non-persistence of the five drugs (p
PB Bmj publishing group
SN 2047-9956
YR 2016
FD 2016-09-01
LK http://hdl.handle.net/10668/19035
UL http://hdl.handle.net/10668/19035
LA en
DS RISalud
RD Apr 8, 2025